- Home
- RYN vs CELC Comparison
RYN vs CELC Comparison
Compare RYN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYN | CELC |
|---|---|---|
| Founded | 1926 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | RYN | CELC |
|---|---|---|
| Price | $21.54 | $98.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $27.25 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 1.4M | 877.1K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 13.42% | N/A |
| EPS Growth | ★ 373.89 | N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | ★ $1,293,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.00 | N/A |
| P/E Ratio | $4.25 | ★ N/A |
| Revenue Growth | ★ 60.70 | N/A |
| 52 Week Low | $21.06 | $7.58 |
| 52 Week High | $32.74 | $103.06 |
Technical Indicators
Market Signals| Indicator | RYN | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 72.64 |
| Support Level | $21.38 | $96.70 |
| Resistance Level | $22.29 | $102.58 |
| Average True Range (ATR) | 0.46 | 5.65 |
| MACD | 0.12 | -0.17 |
| Stochastic Oscillator | 32.52 | 79.51 |
Price Performance
Historical ComparisonAbout RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.